Top

Journal of Gastrointestinal Cancer

Published in:

01-03-2022 | Gastric Cancer | Original Research

Cytotoxic and Apoptotic Effects of Celecoxib and Topotecan on AGS and HEK 293 Cell Lines

Authors: Kimia Badalanloo, Tahereh Naji, Rahim Ahmadi

Published in: Journal of Gastrointestinal Cancer | Issue 1/2022

Abstract

Purpose

This study is aimed to assess the anti-cancer effects of Celecoxib and topotecan against Human Gastric cancer cell line (AGS) in comparison to the control in an in-vitro study.

Methods

In this experimental study, Celecoxib and topotecan was prepared at concentrations of 500, 250, 125, 62.5, 31.2, 15.6 and 7.8 mg/ml. The effect of celecoxib and topotecan separately and in mixed form were investigated on AGS and normal HEK cells. To investigate the cell survival, MTT method was used to study the pathway of apoptosis using flowcytometry and Caspase kits based on colorimetric. Finally, one-way ANOVA and t-test were used to analyze the data.

Results

The results of this study indicated that Celecoxib was cytotoxic against AGS and HEK cell lines. The topotecan indicated a significant cytotoxicity against AGS cells and was not toxic against HEK cell line. Our results indicated that Celecoxib and topotecan have synergist effects against AGS and HEK cell lines and were more effective than separate celecoxib or topotecan.

Conclusion

The mixture of clecoxib and topotecan was more effective than celecoxib and topotecan in separate form. Our results indicated that use mixed forms of treatments can cause excellent therapeutic effects and can cause less side effects.

Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny. 2019;14(1):26.PubMed

Lyons K, Le LC, Pham YT-H, Borron C, Park JY, Tran CT, et al. Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev. 2019;28(5):397–412.PubMedCrossRef

Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42.PubMedCrossRef

Esghaei M, Ghaffari H, Esboei BR, Tapeh ZE, Salim FB, Motevalian M. Evaluation of anticancer activity of Camellia sinensis in the Caco-2 colorectal cancer cell line. Asian Pacific journal of cancer prevention: APJCP. 2018;19(6):1697.PubMedPubMedCentral

Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol: WJG. 2014;20(7):1635.PubMedPubMedCentralCrossRef

Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683–99.PubMedCrossRef

Luo M-X, Long B-B, Li F, Zhang C, Pan M-T, Huang Y-Q, et al. Roles of Cyclooxygenase-2 gene− 765G> C (rs20417) and− 1195G> a (rs689466) polymorphisms in gastric cancer: a systematic review and meta-analysis. Gene. 2019;685:125–35.PubMedCrossRef

Wyatt GL, Crump LS, Young CM, Wessells VM, McQueen CM, Wall SW, et al. Cross-talk between SIM2s and NFκB regulates cyclooxygenase 2 expression in breast cancer. Breast Cancer Res. 2019;21(1):1–12.CrossRef

Chiang S-L, Velmurugan BK, Chung C-M, Lin S-H, Wang Z-H, Hua C-H, et al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep. 2017;7(1):1–11.CrossRef

10.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–95.PubMedCrossRef

11.

Xie L, Yang R-T, Lv K, Zhou H-H, Li Z (2020) Comparison of Low Pre-Emptive Oral Doses of Celecoxib Versus Acetaminophen for Postoperative Pain Management After Third Molar Surgery: A Randomized Controlled Study. Journal of Oral and Maxillofacial Surgery 78 (1):75. e71–75. e76.

12.

Shackleford GM, Mahdi MY, Moats RA, Hawes D, Tran HC, Finlay JL, et al. Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma. PLoS One. 2019;14(1).

13.

Mootz AA, Peyton M, Yenerall P, Avila K, Huffman K, Haruki T, Papari-Zareei M, Stastny V, Girard L, McMillan E (2018) Identification of two small molecules with small cell lung cancer growth inhibition response profiles different from etoposide/topotecan. AACR,

14.

Chabra A, Rahimi-Esboei B, Habibi E, Monadi T, Azadbakht M, Elmi T, et al. Effects of some natural products from fungal and herbal sources on Giardia lamblia in vivo. Parasitology. 2019;146(9):1188–98.PubMedCrossRef

15.

Marques FM, Figueira MM, Schmitt EFP, Kondratyuk TP, Endringer DC, Scherer R, et al. In vitro anti-inflammatory activity of terpenes via suppression of superoxide and nitric oxide generation and the NF-κB signalling pathway. Inflammopharmacology. 2019;27(2):281–9.PubMedCrossRef

16.

Liu B, Yan S, Qu L, Zhu J. Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway. Cancer Cell Int. 2017;17(1):1.PubMedPubMedCentralCrossRef

17.

Rescifina A, Surdo E, Cardile V, Avola R, Graziano ACE, Stancanelli R, et al. Gemcitabine anticancer activity enhancement by water soluble celecoxib/sulfobutyl ether-β-cyclodextrin inclusion complex. Carbohydr Polym. 2019;206:792–800.PubMedCrossRef

18.

Bando T, Fujita S, Nagano N, Yoshikawa S, Yamanishi Y, Minami M, et al. Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils. Biochemistry and biophysics reports. 2017;10:82–7.PubMedPubMedCentralCrossRef

19.

Setiawati A. Celecoxib, a COX-2 selective inhibitor, induces cell cycle arrest at the G2/M phase in HeLa cervical cancer cells. Asian Pac J Cancer Prev. 2016;17(4):1655–9.PubMedCrossRef

20.

Kong Y, Gu C, Zhong D, Zhao X, Lin Q, Wang K, et al. Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx. Eur J Pharm Sci. 2016;81:137–48.PubMedCrossRef

21.

Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA. Multi-reservoir phospholipid shell encapsulating protamine nanocapsules for co-delivery of letrozole and celecoxib in breast cancer therapy. Pharm Res. 2017;34(9):1956–69.PubMedCrossRef

22.

Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NM. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev. 2017;8.

23.

Vallée A, Lecarpentier Y, Vallée J-N. Targeting the canonical WNT/β-catenin pathway in cancer treatment using non-steroidal anti-inflammatory drugs. Cells. 2019;8(7):726.PubMedCentralCrossRef

24.

Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer stem cell potent copper (II)–non-steroidal anti-inflammatory drug complexes. Angew Chem Int Ed. 2016;55(8):2845–50.CrossRef

25.

Zhang P, He D, Song E, Jiang M, Song Y. Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression. PLoS One. 2019;14(10).

26.

Venereo-Sanchez A, Simoneau M, Lanthier S, Chahal P, Bourget L, Ansorge S, et al. Process intensification for high yield production of influenza H1N1 gag virus-like particles using an inducible HEK-293 stable cell line. Vaccine. 2017;35(33):4220–8.PubMedCrossRef

27.

Lobas AA, Karpov DS, Kopylov AT, Solovyeva EM, Ivanov MV, Ilina IY, et al. Exome-based proteogenomics of HEK-293 human cell line: coding genomic variants identified at the level of shotgun proteome. Proteomics. 2016;16(14):1980–91.PubMedCrossRef

28.

Erfani N, Razmkhah M, Talei A, Pezeshki A, Doroudchi M, Monabati A, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet. 2006;165(2):114–20.PubMedCrossRef

29.

Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, et al. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res. 2012;14(1):R20.PubMedPubMedCentralCrossRef

30.

Schernhammer ES, Kang J-H, Chan AT, Michaud DS, Skinner HG, Giovannucci E, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 2004;96(1):22–8.PubMedCrossRef

Title: Cytotoxic and Apoptotic Effects of Celecoxib and Topotecan on AGS and HEK 293 Cell Lines
Authors: Kimia Badalanloo
Tahereh Naji
Rahim Ahmadi
Publication date: 01-03-2022
Publisher: Springer US
Keywords: Gastric Cancer
Celecoxib
Gastric Cancer
Published in: Journal of Gastrointestinal Cancer / Issue 1/2022
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00434-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer

Factors affecting the survival of patients with colorectal cancer using random survival forest

The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

Association of Epidermal Growth Factor 61A>G, Survivin -31G>C, and EFNA1 -1732G>A Polymorphisms with Susceptibility to Colorectal Cancer

Prognostic Role of Peripheral Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

A Case Study on Modeling the Time to Recurrence of Gastric Cancer Patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials